


Bento Biology Bringing New Contactless Clinical Trial Solutions To DPHARM 2024

Bento Bio is honored to sponsor DPHARM 2024 and showcase its transformative at-home clinical trial solutions to increase patient engagement and diversity.

WASHINGTON, DC, UNITED STATES, September 17, 2024 /EINPresswire.com/ -- [Bento Biology](#), a leading technology company transforming clinical trials with at-home bio-sampling and gamified patient engagement, is proud to sponsor the 14th Annual DPHARM®.

Bento Bio Platforms is a new kind of technology company combining contactless clinical trials with frictionless patient monitoring to radically reduce Sponsor costs and increase patient engagement and diversity. Bento's at-home bio-sampling and biosensing tools and white-glove software support allow patients to collect study samples in the comfort of their homes. Similarly, Bento's platform offers frictionless patient-reported outcome monitoring allowing Sponsors to obtain real-time study data and the chance to amend study protocols. Powered by game economies and play-to-learn (P2L) protocols, Bento Bio's participant inclusion



“

BENTO Bio's novel technology platform and product offerings are bringing clinical trials to the patient and changing the game for patient participation and engagement.”

Al Roy, President & CEO, Lupus Research Alliance

platform has delivered unprecedented results including a 100% sample return rate in a recent Lupus study. “BENTO Bio's novel technology platform and product offerings are bringing clinical trials to the patient and changing the game for patient participation and engagement,” noted Al Roy, President & CEO, Lupus Research Alliance.

“With our recent commercialization and global expansion, DHARM comes at an exciting time for us at Bento Bio, and we are thrilled to be a sponsor,” said Dr. Kelly McVearry, Bento Co-founder and President. “Not only has Bento delivered incredible results for our customers by transforming clinical trials into a contactless, efficient,

trust-building, and cost-effective experience, but Bento's technology also supports developments in population genomics, biorepositories, and long-term follow-up requirements for cell and gene

therapy.”

DPHARM attendees can learn more about Bento Bio Platforms and how it can transform their clinical research by contacting Louis Sanquini directly 917-558-0621 or Louis.Sanquini@bentobio.com.

About Bento Biology Platforms Inc. (BENTO)

Bento Bio is on a mission to transform clinical trial participation into an immersive user experience accessible to diverse individuals worldwide, from the comfort of their homes. Bento Bio has pioneered contactless clinical trials with at-home bio-sampling and wearable technologies for the new era of inclusive medicine, starting with self-service participation in decentralized clinical trials (DCT) and frictionless patient-reported outcomes monitoring. Powered by game economies and play-to-learn (P2L) protocols, Bento Bio’s participant inclusion platform radically reduces Sponsor costs & builds trust with distrustful and medically underrepresented communities. To learn more about Bento Bio, visit www.bentobio.com

About Hypatia Project

HYPATIA is trusted by governments, national labs, and the defense industrial base to provide software engineering and AI infrastructure for public benefit missions around the world. The company is a prime contractor, GSA Schedule holder, and SBA-certified Woman-Owned Small Business, distinguished for leading digital transformation programs and building AI software factories and blockchain solutions. In 2024, Hypatia was awarded a Federal 100, the most prestigious award in Federal IT. Since 2017, Hypatia has been a Data Innovation Partner to the United States Department of Commerce, a joint venture program to solve government-wide data challenges. To learn more about Hypatia, visit: www.hypatiaproject.com and <https://www.hypatia-vets.com>.

Evans McMillion

Bento Bio

+1 757-376-9604

evans.mcmillion@bentobio.com

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/743980744>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.